Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

(2019) Josef Coresh et al.   Lancet Diabetes & Endocrinology

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

(2019) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

Association of Urine Albumin Excretion With Incident Heart Failure Hospitalization in Community-Dwelling Adults

(2019) Luke N. Bailey et al.   JACC-Heart Failure

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

(2019) Daniël H. van Raalte et al.   DIABETES CARE

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

(2018) Claire C. J. Dekkers et al.   Current Diabetes Reports

Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD

(2018) Sophie M. van den Belt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

(2018) Vlado Perkovic et al.   Lancet Diabetes & Endocrinology

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk

(2018) Benjamin M. Scirica et al.   JAMA Cardiology

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)

(2018) Mikhail Kosiborod et al.   Cardiovascular Diabetology

Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans

(2017) Carmen A. Peralta et al.   BMC Nephrology

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Is a reduction in albuminuria associated with renal and cardiovascular protection? Apost hocanalysis of the ALTITUDE trial

(2016) H. J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Use of Clinical Decision Support to Improve Primary Care Identification and Management of Chronic Kidney Disease (CKD)

(2016) Cara B. Litvin et al.   Journal of the American Board of Family Medicine

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy

(2015) T. F. Kropelin et al.   Clinical Journal of the American Society of Nephrology

Association of Cardiometabolic Multimorbidity With Mortality

(2015) Emanuele Di Angelantonio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials

(2014) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

Microalbuminuria: target for renoprotective therapy PRO

(2014) Sara S. Roscioni et al.   KIDNEY INTERNATIONAL

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Within-Person Variability in Kidney Measures

(2013) Elizabeth Selvin et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND

(2013) F. P. Brouwers et al.   EUROPEAN HEART JOURNAL

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

(2012) Caroline S Fox et al.   LANCET

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes

(2009) T. Ninomiya et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria

(2008) E. C. Witte et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY